$11.1 M

GALE Mkt cap, 22-Dec-2017
Galena Biopharma Net income (Q1, 2018)-8 M
Galena Biopharma Cash, 31-Mar-20183.5 M
Galena Biopharma EV17.3 M

Galena Biopharma Financials

Galena Biopharma Income Statement

Annual

USDFY, 2016FY, 2017

R&D expense

19.9 m6.1 m

General and administrative expense

12 m15.1 m

Operating expense total

31.9 m21.2 m

EBIT

(31.9 m)

Interest expense

3.5 m462 k

Pre tax profit

(10.9 m)

Income tax expense

243 k253 k

Net Income

(23.5 m)(23.8 m)

Quarterly

USDQ3, 2014Q1, 2015Q2, 2016Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Revenue

1.6 m2.8 m3.4 m

Cost of goods sold

247 k393 k468 k

Gross profit

1.4 m2.4 m2.9 m

Gross profit Margin, %

85%86%86%

R&D expense

7.2 m5.9 m5.7 m5.4 m6.2 m3.6 m2.4 m1.8 m

General and administrative expense

2.9 m3.5 m3.1 m2.8 m2.7 m3.9 m

Operating expense total

7.2 m5.9 m8.6 m9 m9.3 m6.5 m5.1 m5.7 m

EBIT

(13.2 m)(11.1 m)(8.6 m)(9 m)(9.3 m)(6.5 m)(5.1 m)

EBIT margin, %

(815%)(405%)(255%)

Interest expense

297 k242 k158 k91 k519 k1.4 m973 k96 k

Interest income

297 k242 k158 k91 k

Pre tax profit

(6.2 m)

Income tax expense

Net Income

(6.2 m)(10.5 m)(18 m)(16.5 m)5.4 m(6.9 m)(11.7 m)(8 m)

Galena Biopharma Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

47.8 m23.7 m29.7 m18.1 m2.3 m

Accounts Receivable

Inventories

386 k655 k581 k

Current Assets

53.5 m29 m53.6 m37.5 m13.1 m

Goodwill

5.9 m6.1 m5.9 m5.9 m1.9 m

Total Assets

88 m80.5 m82.1 m65.8 m33.5 m

Accounts Payable

2.7 m2.3 m1.6 m840 k11.7 m

Short-term debt

2.1 m3.9 m4.7 m16.4 m8.4 m

Current Liabilities

62.4 m27.2 m57.1 m30.4 m24.6 m

Long-term debt

2.6 m

Total Debt

16.4 m11 m

Total Liabilities

37.2 m31.5 m

Additional Paid-in Capital

188.6 m256.4 m296.7 m335.4 m56.3 m

Retained Earnings

178.9 m215.5 m279.4 m302.9 m(54.2 m)

Total Equity

5.9 m37.1 m13.5 m28.7 m2.1 m

Debt to Equity Ratio

0.6 x

Debt to Assets Ratio

0.2 x

Financial Leverage

14.9 x2.2 x6.1 x2.3 x16.2 x

Quarterly

USDQ3, 2014Q1, 2015Q2, 2016Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Cash

24.6 m52.9 m34.8 m34.7 m19.6 m24.5 m27.6 m3.5 m

Accounts Receivable

1.1 m1.8 m

Inventories

450 k637 k1.4 m

Current Assets

28.5 m57.3 m54.2 m37.9 m45.3 m44.5 m42 m13.1 m

Goodwill

5.9 m6.1 m5.9 m5.9 m5.9 m5.9 m5.9 m1.9 m

Total Assets

79.5 m108.6 m82.7 m66.4 m73.8 m72.8 m70.3 m33.5 m

Accounts Payable

3.4 m3.3 m1.2 m1 m1.3 m894 k1.2 m11.5 m

Short-term debt

4.2 m4 m4.2 m3.7 m23.2 m23.7 m12.6 m8.5 m

Current Liabilities

31.6 m34 m37.1 m42.2 m47.2 m42.5 m36.3 m25.7 m

Long-term debt

5.1 m3.5 m1.5 m1.2 m

Total Debt

9.7 m

Total Liabilities

34.8 m

Additional Paid-in Capital

242.2 m288.9 m296 m312.1 m314.6 m325.2 m345.7 m60.9 m

Retained Earnings

207.5 m226 m259.7 m295.9 m290.5 m297.4 m314.7 m(62.2 m)

Total Equity

30.9 m32.4 m12.4 m20.3 m23.9 m27.2 m(1.3 m)

Financial Leverage

2.6 x2.6 x5.3 x3.6 x3 x2.6 x-25.4 x

Galena Biopharma Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(76.7 m)(36.6 m)(63.9 m)(23.5 m)(23.8 m)

Accounts Receivable

Inventories

Accounts Payable

8.4 m

Cash From Operating Activities

(11 m)

Cash From Investing Activities

1.8 m

Cash From Financing Activities

5.5 m

Quarterly

USDQ3, 2014Q1, 2015Q2, 2016Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

(6.2 m)(10.5 m)(18 m)(16.5 m)5.4 m(6.9 m)(11.7 m)(8 m)

Accounts Receivable

1.1 m1.8 m

Inventories

450 k637 k1.4 m

Accounts Payable

3.4 m3.3 m1.2 m1 m1.3 m894 k1.2 m(240 k)

Cash From Operating Activities

(5.4 m)

Long-term Borrowings

(589 k)

Cash From Financing Activities

4.7 m

Galena Biopharma Ratios

USDY, 2018

EV/CFO

-3.2 x

Financial Leverage

-25.4 x
Report incorrect company information